Drug Safety

Adverse Effects FDA Side Effects Counterfeit Medications Regulatory Actions Toxicology Regulatory Affairs Substance Abuse Tianeptine Suicidal Thoughts Adverse Events GLP-1 Agonists FDA Warnings Illegal Drugs Medication Trust Cannabis Products Risks of Drug Use Harm Reduction Counterfeit Pharmaceuticals Addiction Drug Effectiveness Therapeutic Index Regulatory Compliance Clinical Efficacy Quality Control Pharmaceutical Companies Chemical Analysis Market Withdrawals Market Withdrawal Adverse Drug Events Microbial Contamination Clinical Trials Overdose Awareness Quality Standards Public Health Risks Spurious Drugs Regulation Medical Research Adverse Reactions Public Health Contaminated Food Military Drug Composition Fentanyl Overdose Risks Regulatory Processes

Utah Panel Advances Kratom Ban as Lawmakers Split on Regulation

After testimony on addiction risks, a Senate committee sent a statewide prohibition bill to the floor.

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Ventyx’s NLRP3 Drug Cuts Inflammation Markers in Phase 2, Shares Soar

FDA Approves Weekly Leqembi Autoinjector for At-Home Maintenance in Early Alzheimer’s

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research